MGMT and neoplasm: A single dose of AMONs (10.5 mg kg−1; IV) in combination with 5 Gy local radiation achieved about 50% MGMT protein knockdown in our animal H460 subcutaneous tumor model, and this dose is comparable and scalable to the 30–50 mg kg−1 week−1 dose approved in treating Duchenne muscular dystrophy in clinical trial.